Category Archives: Inducement to Infringe

DC ineligibility decision erroneous as claims not “solely directed to the printed matter”

C. R. Bard, et al. v. AngioDynamics, Inc. Docket No. 2019-1756, -1934 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1756.OPINION.11-10-2020_1683097.pdf) REYNA, SCHALL, STOLL November 10, 2020 Brief Summary:  DC erroneously granted JMOL based on expert mistake and conclusion that printed matter made claims patent ineligible under section … Continue reading

Posted in Inducement to Infringe, Infringement, Patent Eligibility (101), Patentability | Leave a comment

Induced infringement decision reversed (“subjective bad faith”); eligibility decision affirmed (“improving a basic function of a computer”)

TecSec, Inc. v. Adobe Inc., et al. Docket No. 2019-2192, -2258 PROST, REYNA, TARANTO October 23, 2020 Brief Summary:  DC incorrectly excluded evidence of induced infringement (“subjective bad faith”) but correctly found patent eligibility (“directed to improving a basic function … Continue reading

Posted in Inducement to Infringe, Patent Eligibility (101), Section 101 (see also Patentability), Software, Uncategorized | Leave a comment

Teva’s ANDA carve-out does not save it from induced infringement (“when the provider of an identical product knows of and markets the same product for intended direct infringing activity, the criteria of induced infringement are met”)

GlaxoSmithKline LLC, et al. v. Teva Pharmaceuticals USA, Inc. Docket No. 2018-1976, -2023 PROST, NEWMAN, MOORE October 2, 2020 Brief Summary:  GSK appealed DC judgment of a matter of law (JMOL) finding no induced infringement of RE40,000 by Teva’s Coreg® … Continue reading

Posted in Damages, Generics / ANDA, Inducement to Infringe, Willfullness | Leave a comment

Horizon’s OB ‘913 claim 12 survives obviousness challenge (Pennsaid® for osteoarthritis)

HZNP Medicines LLC et al. v. Actavis Laboratories UT, Inc. Docket No. 2017-2149, -2152-53, -2202-3, -2206 PROST, NEWMAN, REYNA October 10, 2019 Brief Summary: DC findings of indefiniteness, no induced infringement, and no invalidity for obviousness regarding Horizon’s OB patents … Continue reading

Posted in Claim Construction, Generics / ANDA, Indefiniteness, Inducement to Infringe, Infringement, Obviousness, Uncategorized | Leave a comment

Grant of SJ of non-infringement reversed due to “genuine dispute of material fact on…whether the…software was capable of infringing uses”

NeuroGrafix, et al. v. Brainlab, Inc. et al. Docket No. 2018-2363 NEWMAN, O’MALLEY, TARANTO October 7, 2019 Non-precedential Brief Summary: Grant of SJ reversed due to “genuine dispute of material fact on…whether the…software was capable of infringing uses”. Summary: NeuroGrafix … Continue reading

Posted in Claim Construction, Inducement to Infringe, Infringement, Uncategorized | Leave a comment

DC grant of SJ of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

DC grant of SJ to Genentech of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

Omega Patents, LLC v. CalAmp Corp.

Docket No. 2018-1309 PROST, DYK, WALLACH April 8, 2019 Brief summary: DC decision finding infringement of ‘727 claim 1 affirmed; others reversed and remanded for state of mind analysis and to determine whether there were predicate acts of infringement; willfulness … Continue reading

Posted in Attorney's Fees, Claim Construction, Damages, Inducement to Infringe, Infringement, Willfullness | Leave a comment

Grunenthal Gmbh et al. v. Alkem Labs. Ltd., Hikma Pharm., Actavis et al.

Docket No. 2017-1153, -2048-50 REYNA, TARANTO, CHEN March 28, 2019 Brief summary: DC decisions of nonobviousness of Grunenthal’s polymorph claims, no induced or contributory infringement due to section viii carve-out, and specific utility of the claimed polymorph affirmed. Summary: Alkem … Continue reading

Posted in Anticipation (35 USC 102), Contributory Infringement, Generics / ANDA, Inducement to Infringe, Inherency, Obviousness, Utility | Leave a comment

Mark A. Barry v. Medtronic, Inc.

Docket No. 2017-2463 PROST, MOORE, TARANTO January 24, 2019 Brief summary: DC and jury conclusions of no invalidity and infringement affirmed (e.g., the invention was not in “public use” as the use was experimental, no § 102(b) on-sale bar, no … Continue reading

Posted in Anticipation (35 USC 102), Conception and Reduction to Practice, Experimental Use, Inducement to Infringe, Inequitable Conduct, Infringement, Preamble, Public Use | Tagged | Leave a comment